A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportice Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic (MDS)

  • Tiong, Ing Soo (Primary Chief Investigator (PCI))
  • Malherbe, Maturos (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date9/03/23 → 9/03/25

Keywords

  • clinical trial
  • Myelodysplastic syndromes
  • haematology

Clinical Trial Phase

  • Phase II
  • Phase III (a & b)